Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm
Thrombosis is a more common occurrence in cancer patients compared to the general population and is one of the main causes of death in these patients. Low molecular weight heparin (LMWH) has been the recognized standard treatment for more than a decade, both in cancer-related thrombosis and in its p...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-05-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/5/1144 |
id |
doaj-d1dd048f93b442dfb8437e03b82088ca |
---|---|
record_format |
Article |
spelling |
doaj-d1dd048f93b442dfb8437e03b82088ca2020-11-25T02:02:48ZengMDPI AGCancers2072-66942020-05-01121144114410.3390/cancers12051144Direct Oral Anticoagulants in Cancer Patients. Time for a Change in ParadigmMarek Z. Wojtukiewicz0Piotr Skalij1Piotr Tokajuk2Barbara Politynska3Anna M. Wojtukiewicz4Stephanie C. Tucker5Kenneth V. Honn6Department of Oncology, Medical University of Białystok, 12 Ogrodowa St., Białystok 15-027, PolandDepartment of Oncology, Medical University of Białystok, 12 Ogrodowa St., Białystok 15-027, PolandDepartment of Oncology, Medical University of Białystok, 12 Ogrodowa St., Białystok 15-027, PolandDepartment of Philosophy and Human Psychology, Medical University of Białystok, 37 Szpitalna St., 15-295 Białystok, PolandDepartment of Philosophy and Human Psychology, Medical University of Białystok, 37 Szpitalna St., 15-295 Białystok, PolandBioactive Lipids Research Program, Department of Pathology-School of Medicine, Detroit, MI 48202, USABioactive Lipids Research Program, Department of Pathology-School of Medicine, Detroit, MI 48202, USAThrombosis is a more common occurrence in cancer patients compared to the general population and is one of the main causes of death in these patients. Low molecular weight heparin (LMWH) has been the recognized standard treatment for more than a decade, both in cancer-related thrombosis and in its prevention. Direct oral anticoagulants (DOACs) are a new option for anticoagulation therapy. Recently published results of large randomized clinical trials have confirmed that DOAC may be a reasonable alternative to LMWH in cancer patients. The following review summarizes the current evidence on the safety and efficacy of DOAC in the treatment and prevention of cancer-related thrombosis. It also draws attention to the limitations of this group of drugs, knowledge of which will facilitate the selection of optimal therapy.https://www.mdpi.com/2072-6694/12/5/1144thrombosiscancertreatmentprophylaxisanticoagulantsDOAC |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Marek Z. Wojtukiewicz Piotr Skalij Piotr Tokajuk Barbara Politynska Anna M. Wojtukiewicz Stephanie C. Tucker Kenneth V. Honn |
spellingShingle |
Marek Z. Wojtukiewicz Piotr Skalij Piotr Tokajuk Barbara Politynska Anna M. Wojtukiewicz Stephanie C. Tucker Kenneth V. Honn Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm Cancers thrombosis cancer treatment prophylaxis anticoagulants DOAC |
author_facet |
Marek Z. Wojtukiewicz Piotr Skalij Piotr Tokajuk Barbara Politynska Anna M. Wojtukiewicz Stephanie C. Tucker Kenneth V. Honn |
author_sort |
Marek Z. Wojtukiewicz |
title |
Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm |
title_short |
Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm |
title_full |
Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm |
title_fullStr |
Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm |
title_full_unstemmed |
Direct Oral Anticoagulants in Cancer Patients. Time for a Change in Paradigm |
title_sort |
direct oral anticoagulants in cancer patients. time for a change in paradigm |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2020-05-01 |
description |
Thrombosis is a more common occurrence in cancer patients compared to the general population and is one of the main causes of death in these patients. Low molecular weight heparin (LMWH) has been the recognized standard treatment for more than a decade, both in cancer-related thrombosis and in its prevention. Direct oral anticoagulants (DOACs) are a new option for anticoagulation therapy. Recently published results of large randomized clinical trials have confirmed that DOAC may be a reasonable alternative to LMWH in cancer patients. The following review summarizes the current evidence on the safety and efficacy of DOAC in the treatment and prevention of cancer-related thrombosis. It also draws attention to the limitations of this group of drugs, knowledge of which will facilitate the selection of optimal therapy. |
topic |
thrombosis cancer treatment prophylaxis anticoagulants DOAC |
url |
https://www.mdpi.com/2072-6694/12/5/1144 |
work_keys_str_mv |
AT marekzwojtukiewicz directoralanticoagulantsincancerpatientstimeforachangeinparadigm AT piotrskalij directoralanticoagulantsincancerpatientstimeforachangeinparadigm AT piotrtokajuk directoralanticoagulantsincancerpatientstimeforachangeinparadigm AT barbarapolitynska directoralanticoagulantsincancerpatientstimeforachangeinparadigm AT annamwojtukiewicz directoralanticoagulantsincancerpatientstimeforachangeinparadigm AT stephaniectucker directoralanticoagulantsincancerpatientstimeforachangeinparadigm AT kennethvhonn directoralanticoagulantsincancerpatientstimeforachangeinparadigm |
_version_ |
1724951476862713856 |